Safety and Efficacy Results from the Open Label Extension of a Phase 2 Trial of Risankizumab, a Selective IL-23p19 Inhibitor in Patients with Active Psoriatic Arthritis
Kim Papp, Melinda Gooderham, Akimichi Morita et. al.

Nov 13th, 2019 - Background/Purpose: Psoriatic arthritis (PsA) is characterized by peripheral synovitis, enthesitis, dactylitis and spondylitis, and IL-23 is involved in the pathogenesis of these conditions either directly or indirectly. Risankizumab (RZB), a potent humanized IgG1 monoclonal antibody and selective IL23p19 inhibitor, exhibited superior efficacy vs placebo via ACR responses and PASI scores in pat...

Cluster-based Spondyloarthritis Phenotypes Defined at Baseline Are Predictive of Different Severity Outcomes at 5-Year in the DESIR Cohort
Félicie Costantino, Philippe Aegerter, Anna Moltó et. al.

Nov 12th, 2019 - Background/Purpose: The course of axial spondyloarthritis (SpA) is heterogeneous and remains to be better defined. DESIR is a longitudinal French cohort of early undifferentiated axial SpA, allowing to define different disease courses. We recently performed a cluster analysis, based on baseline characteristics and identified 2 SpA clusters: one, characterized by an isolated axial disorder (A fo...

Profiling Behavioral and Psychological Symptoms in Children with Spondyloarthritis and Polyarthritis
Anne McHugh, Avis Chan, Carolyn Herrera et. al.

Nov 12th, 2019 - Background/Purpose: Mental health disorders are thought to be common in patients with rheumatic disease, but studies examining behavioral issues in patients with juvenile idiopathic arthritis (JIA) have shown mixed results. This may be because JIA comprises a heterogeneous group of diseases and few studies examine psychopathology in different subtypes and disease activity states. This study aim...

Patients with Axial Spondyloarthritis Have Abnormal Microarchitecture Despite Normal Areal Bone Mineral Density and Trabecular Bone Score by DXA
Dalit Ashany, Susan Goodman, Haley Tornberg et. al.

Nov 12th, 2019 - Background/Purpose: Axial Spondyloarthritis (axSpA) is characterized by abnormal bone formation that produces syndesmophytes, while paradoxically, inflammation causes increased bone resorption and skeletal fragility. Detection of osteoporosis using DXA can be challenging as syndesmophytes falsely elevate spine areal bone mineral density (aBMD). In contrast, high-resolution peripheral QCT (HRpQC...

Study of Vertebral Fracture Prevalence and Scanographic Bone Attenuation Coefficient of the First Lumbar Vertebra (SBAC-L1) in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis vs. Cont...
Marine Fauny, Eliane Albuisson, Elodie Bauer et. al.

Nov 12th, 2019 - Background/Purpose: Osteoporosis is a common disease whose prognosis can be seriously impacted by the development of fractures that lead to functional limitations and may even have life-threatening sequelae. This disease is often under-screened, especially in at-risk populations that require multidisciplinary care such as patients with rheumatoid arthritis (RA) and ankylosing spondylitis (AS). ...

Shared and Differing Risk Factors for PsA, Psoriasis, AS, and RA: A Series of Case-control Studies
Alexis Ogdie, Xingmei Wang, Thorvardur J Love et. al.

Nov 12th, 2019 - Background/Purpose: While a handful of clinical risk factors for the development of inflammatory diseases have been identified, to date, no studies have compared risk factors across multiple inflammatory diseases. The objective of this study was to compare the strength of association of selected potential risk factors for the development of psoriasis, PsA, RA, and AS. Methods: We performed a se...

Comparison of Comorbidity in Spondyloarthritis: Influence on Inflammatory Activity in Patients with Psoriatic Arthritis
Luis Gomez-Lechon, Maria Elisa Acosta, Guadalupe Manzano Canabal et. al.

Nov 12th, 2019 - Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous disease that is included in the group of spondyloarthritis. Although PsA has its own clinical characteristics, it has a relatively specific comorbidity in relation to the rest of the entities that make up the group. The most frequent comorbidities in PsA are emotional disorders (anxiety and depression) and obesity. Its presence im...

Can Biologics “Prevent” the Development of Psoriatic Arthritis in Psoriasis Patients? Data from a Large University Hospital Cohort in Argentina
Luciano Fernando Lo Giudice, Maria Laura Acosta Felquer, Luis Daniel Mazzuoccolo et. al.

Nov 12th, 2019 - Background/Purpose: As psoriasis (Pso) commonly precedes psoriatic arthritis (PsA), an important unanswered question is whether treatment of Pso might influence the development of PsA in patients with psoriasis. The objective of this study was to analyze the incidence of PsA in a large cohort of patients with PsO according to different treatments, with the hypothesis that treatment with biologi...

Distinctive Pattern of LTBI Screening Parameters in Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA) in Endemic Areas
Andrea Shimabuco, Ana Cristina de Medeiros Ribeiro, Renata Miossi et. al.

Nov 12th, 2019 - Background/Purpose: Despite late tuberculosis infection (LTBI) screening before anti-TNF treatment, TB reactivation/new exposure in endemic areas remains a relevant problem. The specific analysis of Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA) screening parameters has not been evaluated previously and may provide clues to improve risk assessment for these diseases. Our objective is...

Description and Prevalence of Spondyloarthritis in Unselected Patients with Psoriasis, Acute Anterior Uveitis, and Inflammatory Bowel Disease Presenting with Undiagnosed Back Pain
Walter P. Maksymowych, Raj Carmona, Jonathan Chan et. al.

Nov 12th, 2019 - Background/Purpose: There is limited prospective data as to the frequency of axial spondyloarthritis (axSpA) in unselected patients referred to rheumatologists with undiagnosed back pain who have presented with acute anterior uveitis (AAU), psoriasis, or colitis to their respective specialists. It is also unclear which clinical features discriminate between axSpA and non-specific causes of back...

Alcohol Consumption as a Predictor of the Progression of Spinal Structural Damage in Axial Spondyloarthritis: Data from the Catholic Axial Spondyloarthritis COhort (CASCO)
Hong Ki Min, Seung-Ki Kwok 2 and Sang-Heon Lee, Konkuk university medical center et. al.

Nov 12th, 2019 - Background/Purpose: The purpose of the present study was to demonstrate the predicting factors of spinal structural damage in axial spondyloarthritis (axSpA) in a prospective cohort study. Methods: AxSpA patients were enrolled from a single tertiary hospital in a prospective cohort. Baseline data were collected, and 2 year follow-up radiographic data were collected. We analyzed the progression ...

AxSpA Patients with Symptom Onset < 30 Years Have More Structural Lesions on MRI of the Sacroiliac Joints When Fulfilling the Modified New York Criteria
Manouk de Hooge, Ann-Sophie De Craemer, Thomas Renson et. al.

Nov 12th, 2019 - Background/Purpose: The modified New York criteria (mNY) combine clinical symptoms with radiographic sacroiliitis on conventional pelvic radiographs (X-SI) classifying radiographic axial SpA patients (r-axSpA). AxSpA is known to typically start in the third era of life but there is a diagnostic delay of ±7 years. As the mNY criteria classify the most typical and severe expression of axSpA it is...

Treatment Preferences in Patients with Axial Spondyloarthritis
Dafne Capelusnik, Emilce Schneeberger, Leonela Lysseth Macias Oviedo et. al.

Nov 12th, 2019 - Background/Purpose: Due to the increasing tendency of involving patients in decisions regarding their health care and knowing the need for further research on patients’ preferences about treatment and adherence, the aim of this study was to evaluate the treatment preferences of patients with Axial Spondyloarthritis (axSpA) and to identify the factors associated with their choice. Methods: Patie...

Ixekizumab in Non-Radiographic Axial Spondyloarthritis: Primary Results from a Phase 3 Trial
Atul Deodhar, Désirée van der Heijde, Lianne Gensler et. al.

Nov 12th, 2019 - Background/Purpose: Ixekizumab (IXE), a high affinity IL-17A monoclonal antibody, previously showed efficacy in AS/radiographic-axSpA1,2. COAST-X (NCT02757352) is a phase 3 study that assessed efficacy and safety of IXE in patients (pts) with active nr-axSpA and objective signs of inflammation. Methods: COAST-X was a 52-wk, randomized, double-blind, PBO-controlled study enrolling adults with an...

Relationship Between Structural Spine Involvement and the Scanographic Bone Attenuation Coefficient of L1 in a Population of 73 Patients with Ankylosing Spondylitis
Marine Fauny, Frank VERHOEVEN, Edem Allado et. al.

Nov 12th, 2019 - Background/Purpose: Thoracic and/or thoraco-abdomino-pelvic (TAP) Computed Tomography (CT) may be performed during the follow up of patients with ankylosing spondylitis (AS) and are able to assess vertebral fracture and recently to assess bone fragility thought the scanographic bone attenuation coefficient of the first lumbar vertebra (SBAC-L1).    The objective is to evaluate the correlation b...

What Is Axial Spondyloarthritis? A Latent Class and Transition Analysis in the SPACE and DESIR Cohorts
Alexandre Sepriano, Sofia Ramiro, Désirée van der Heijde et. al.

Nov 12th, 2019 - Background/Purpose: Axial spondyloarthritis (axSpA) is a disease with a rather heterogeneous presentation that may be difficult to diagnose. Classification criteria, such as the ASAS criteria, developed and validated against the gold-standard ‘expert diagnosis’, exist,  but may suffer from circularity because features deemed important by experts may have got a too prominent, and therefore biase...

Frailty in Ankylosing Spondylitis, Psoriatic Arthritis, and Rheumatoid Arthritis: Data from a National Claims Database
Sarah Lieber, Mangala Rajan, Sebastian E. Sattui et. al.

Nov 12th, 2019 - Background/Purpose: Frailty, a state of decreased homeostatic reserve, is associated with increased disability and mortality, independent of age. Frailty has been evaluated in large datasets using validated algorithms in the elderly. Although frailty has been investigated in several rheumatic diseases, including RA, to our knowledge, frailty has not been investigated in AS and PsA, which often ...

Efficacy and Safety of Tocilizumab Treatment for Anti–human T Lymphotropic Virus Type I Antibody–positive Rheumatoid Arthritis
Yushiro Endo, Kunihiko Umekita, Hideki Nakamura et. al.

Nov 12th, 2019 - Background/Purpose: The asymptotic individuals with the human T lymphotropic virus type I (HTLV-I) infection rarely develop adult T cell leukemia/lymphoma (ATL) or HTLV-I–associated myelopathy (HAM). In addition, HTLV­1 infection is also associated with rheumatic disease such as HTLV-I–associated arthropathy, rheumatoid arthritis (RA), and Sjogren’s syndrome. The HTLV-I virus infects not only p...

5-years Treatment Effect of TNF Alpha Inhibitor in Early Axial Spondyloarthritis and Associated Factors: An Inverse Probability Weighting Analysis of the DESIR Cohort
Marion Pons, Sylvie Chevret, Karine Briot et. al.

Nov 12th, 2019 - Background/Purpose: Only scarce date is available on the long term treatment effect in a real-life setting (i.e. effectiveness) of TNFi in early axial SpA forms and its predisposing associated factors; furthermore, unbiased evaluation of treatment effect in non-randomized clinical trials is challenging, and new methods have been developed to overcome prescription bias.  The objectives of the st...

Achilles Tendon Enthesitis and Disease Burden in Psoriatic Arthritis and Axial Spondyloarthritis: Baseline Results from a Randomized Controlled Trial
Frank Behrens, Philipp Sewerin, Eugenio de Miguel et. al.

Nov 12th, 2019 - Background/Purpose: Enthesitis is a common feature of Spondyloarthritis (SpA)1. Enthesitis at the Achilles tendon is an important manifestation with impact on function which is often refractory to standard NSAID/corticosteroid treatment1,2. ACHILLES is a double blind, placebo-controlled, multicenter Phase 3 trial designed to investigate the efficacy of secukinumab on enthesitis by clinical as w...

Efficacy and Safety of Upadacitinib in a Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 2/3 Clinical Study of Patients with Active Ankylosing Spondylitis
Désirée van der Heijde, In-Ho Song, Aileen Pangan et. al.

Nov 12th, 2019 - Background/Purpose: Patients (pts) with ankylosing spondylitis (AS) who have an inadequate response/contraindication to NSAIDs have limited treatment options other than biologics. The Janus kinase (JAK) pathway is a potential therapeutic target in AS. This study assessed the efficacy and safety of upadacitinib (UPA), a selective JAK1 inhibitor, in pts with active AS. Methods: In this double-bli...

Serum Metabolomic Analysis of Psoriatic Arthritis Using Solid Phase Microextraction – Liquid Chromatography – High-Resolution Mass Spectrometry Identifies Putative Disease Activity Markers
Vinod Chandran, Nikita Looby, Nathaly Reyes-Garces et. al.

Nov 12th, 2019 - Background/Purpose: Disease activity in psoriatic arthritis (PsA) is often difficult to assess but drives treatment decisions, joint damage and long-term outcomes. We aimed to identify serum markers for PsA disease activity using metabolomics. Methods: Serum samples were obtained from a cohort of carefully phenotyped patients with PsA satisfying CASPAR criteria (n=30, 15 males, mean age 48 year...

Uveitis in 320 Patients with Psoriatic Arthritis. Epidemiology, Clinical Features and Biological Treatment: Study from a Single University Center
Iñigo Gonzalez-Mazon, Lara Sanchez-Bilbao, Natalia Palmou-Fontana et. al.

Nov 12th, 2019 - Background/Purpose: Uveitis is an extra articular manifestation of psoriatic arthritis (PsA). Uveitis may be more chronic Biological therapy, especially monoclonal TNF inhibitors, are useful to prevent and to treat refractory non-infectious uveitis. However, other biologics had been related to paradoxical uveitis. Our aim was to assess a) the epidemiological and clinical features of uveitis ass...

Pregnancy Rates and Outcomes in Early Axial Spondyloarthritis: Analysis of the DESIR Cohort
Marion Pons, Nathalie Costedoat-Chalumeau, Karine Briot et. al.

Nov 12th, 2019 - Background/Purpose: Only scarce data is available on regarding pregnancy rates and pregnancy outcomes in early axial spondyloarthritis (axSpA). The objectives of this study were to estimate the probability of achieving a clinical pregnancy and presenting an unfavorable pregnancy outcome, and determined their associated factors, in this population. Methods: Observational prospective French cohor...

What Are the Consequences of Spinal Ankylosis on the Bone Trabecular Fragility Assessed on CT- scan in Patients with Ankylosing Spondylitis?
Marine Fauny, Caroline Morizot, Edem Allado et. al.

Nov 12th, 2019 - Background/Purpose: Computed Tomography (CT) is sometimes performed during the follow up of patients with ankylosing spondylitis (AS) to screen comorbidities or complications. Thoracic or thoraco-abdomino-pelvic (TAP) CT have demonstrated their ability to depict vertebral fracture and recently to assess trabecular bone fragility though the scanographic bone attenuation coefficient (SBAC) on lum...

Higher Disease Activity Is Associated with More Spinal Radiographic Progression in Patients with Axial Spondyloarthritis Independently of Prior Exposure to TNF Inhibitors
Alexandre Sepriano, Sofia Ramiro, Stephanie Wichuk et. al.

Nov 12th, 2019 - Background/Purpose: The association between disease activity and spinal radiographic progression in radiographic axial spondyloarthritis (r-axSpA) has been previously shown in a cohort of patients (pts) not being treated with TNF inhibitors (TNFi).1 We aimed to test the possible association between disease activity and spinal radiographic progression in r-axSpA in a real-life cohort, also inclu...

Beneficial Effect of Angiotensin Receptor Blocker in a Spondyloarthritis Animal Model
Seung-Cheol Shim, Jin-Sun Choi, Ji-Young Kim 2 and Chan-Geol Park et. al.

Nov 11th, 2019 - Background/Purpose: Non-steroidal anti-inflammatory drugs (NSAIDs) have been shown to be efficacious in the treatment of the signs and symptoms of spondyloarthritis (SpA). However, NSAIDs have a variety of side effects on gastrointestinal tract, kidney, and cardiovascular system. Angiotensin II (AT II) mediates several pro-inflammatory responses by signaling through AT type I receptor (AT1R). T...

Biologic Use and Reasons for Switching Biologic Therapy in Patients with Non-radiographic Axial Spondyloarthritis in the United States:Findings from a US Survey
Atul Deodhar, Theresa Hunter, Elizabeth Holdsworth et. al.

Nov 11th, 2019 - Background/Purpose: The FDA approved the first biologic for the treatment of nr-axSpA in the US in March 2019. The objective of our study was to describe biologic use and reasons for switching biologic therapy among patients with non-radiographic axial spondyloarthritis (nr-axSpA). Methods: Data from a real world, cross-sectional survey of rheumatologists and their consulting nr-axSpA patients ...

Clinical Characteristics and Treatment Profiles of Patients with Ankylosing Spondylitis Who Initiated Secukinumab and Other Biologics: Results from the Corrona Psoriatic Arthritis/Spondyloarthritis...
Alexis Ogdie, Mei Liu, Sabrina Rebello et. al.

Nov 11th, 2019 - Background/Purpose: Secukinumab is the only non–tumor necrosis factor inhibitor biologic therapy approved for the treatment of ankylosing spondylitis (AS) in the United States. Patients with AS in clinical trials who receive biologics, including secukinumab, may not be representative of those treated in real-world clinical practice due to differences in patient characteristics, practice pattern...

Predicting ASDAS Inactive Disease After 6 Months of TNFi Treatment in Bio-Naive Axial Spondyloarthritis Patients Treated in Clinical Practice – Results from the EuroSpA Collaboration
Lykke Midtbøll Ørnbjerg, Stylianos Georgiadis, Ulf Lindström et. al.

Nov 11th, 2019 - Background/Purpose: Tumor necrosis factor inhibitors (TNFi) have vastly improved prognosis in patients with axial spondyloarthritis (axSpA). However, many patients treated with TNFi still fail to achieve a treatment target of remission. Hence, the aim of this study was to construct and validate a prediction model for achievement of Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive ...

Periarticular Inflammation and Bone Marrow Oedema Are Important in the Evaluation of Enthesitis on MRI in Patients with Peripheral and Axial SpA
Xenofon Baraliakos, Philipp Sewerin, Eugenio de Miguel et. al.

Nov 11th, 2019 - Background/Purpose: Enthesitis is a hallmark feature of Spondyloarthritis (SpA), and frequently localizes at the Achilles tendon1. Enthesitis is predominantly measured with clinical scores like Leeds Enthesitis Index (LEI), however, magnetic resonance imaging (MRI) might represent a more sensitive tool to recognize enthesitis in both, bone and soft tissues2, providing insight about the potentia...

Primary 1-Year Data of Ixekizumab in Biologic Disease-Modifying Anti-rheumatic Drug-Naïve Patients with Radiographic Axial Spondyloarthritis Including Data in Patients Rerandomized from Adalimumab ...
Cheng-Chung Wei, Lianne Gensler, Jessica Walsh et. al.

Nov 11th, 2019 - Background/Purpose: During 16 weeks of blinded treatment, ixekizumab (IXE) and an adalimumab (ADA) active reference arm were found superior to placebo (PBO) in improving signs and symptoms of radiographic axial spondyloarthritis (r-axSpA).1 Here, we assess the safety and efficacy of continuous treatment with IXE through 52 weeks in patients with r-axSpA and describe clinical response at Week 52...

Memory ex-Th17 Cells Contribute to Synovial Inflammation in Spondyloarthritis
SO-HEE JIN, Pu-Reum PARK, Ji Hyun KANG et. al.

Nov 11th, 2019 - Background/Purpose: Spondyloarthritis (SpA) is characterized by inflammation of the synovium. An increase in the number of Th17cells in SpA has been reported. However, it is known that Th17 cells exhibit considerable plasticity, at sites of autoimmune inflammation. Th17 cells can switch to become IL-17 and IFN-r producing ex-Th17 cells. The aim of this study was to investigate the human ex-Th17...

Microbiome in Offspring of Ankylosing Spondylitis Patients
Matthew Stoll, Kimberly DeQuattro, Zhixiu Li et. al.

Nov 11th, 2019 - Background/Purpose: Spondyloarthritis (SpA) results from the interplay between genetic and environmental factors. An emerging factor is the human intestinal microbiota, which multiple studies in children and adults have shown to be abnormal in SpA patients, including enthesitis-related arthritis (ERA) and Ankylosing Spondylitis (AS). Considering the microbiota pathogenic, we may have the opport...

Systematic Literature Review and Network Meta-Analysis Comparing Incidence of Uveitis and IBD in Axial Spondyloarthritis Patients Treated with Anti-TNF versus Anti-IL17A in Placebo Controlled Rando...
Damien Roche, Martin Badard, Laurent Boyer et. al.

Nov 11th, 2019 - Background/Purpose: Inflammatory bowel diseases (IBD) and anterior uveitis (AU) are frequent extra-articular features of axial spondyloarthritis (axSpA). Although effect of anti-TNF on IBD and AU are well known, data are lacking for anti-IL17A.  Our objective was to assess and compare the incidence of IBD and AU in axSpA patients treated with anti-TNF and anti-IL17A. Methods: A systematic liter...

Subcutaneous Secukinumab 150 Mg Provides Rapid and Sustained Relief in Total and Nocturnal Back Pains, Morning Stiffness, and Fatigue in Patients with Active Ankylosing Spondylitis over 4 Years
Helena Marzo-Ortega, Corinne Miceli-Richard, Sonja Gill et. al.

Nov 11th, 2019 - Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory condition. Pain, stiffness, and fatigue are reported as the most troubling symptoms by 70–80%, 20–40%, and 50–60% of patients (pts) with AS, respectively.1-5 Early and sustained relief of these symptoms are essential for effective AS management.4,6 Secukinumab (SEC) provided sustained relief in pain and fatigue in AS pts ...

A Novel MK2 Inhibitor for the Treatment of Ankylosing Spondylitis and Other Inflammatory Diseases
Francisco Ramírez-Valle, Mary Adams, Lisa Beebe et. al.

Nov 11th, 2019 - Background/Purpose: Post-transcriptional control of cytokine and chemokine gene expression is an important checkpoint during inflammation. The MAPKAPK2 (MK2) pathway in particular is critical in regulating the expression of TNF-α and other inflammatory factors by promoting the stability and translation of their transcripts (Kotlyarov 1999 Nat Cell Biol; Neininger 2002 J Biol Chem). Illustrating...

Long-term Clinical Outcome of Anti-TNF Treatment in Patients with Early Axial Spondyloarthritis: 10-year Data of the Etanercept vs. Sulfasalazin in Early Axial Spondyloarthritis Trial
Fabian Proft, Murat Torgutalp, Anja Weiß et. al.

Nov 11th, 2019 - Background/Purpose: Long-term data on anti-TNF treatment in patients with early axial spondyloarthritis (SpA) is scarce. The objective of this analysis was to assess the long-term clinical efficacy (up to 10 years of treatment) of a tumor necrosis factor (TNF) inhibitor etanercept (ETN) in patients with early axial spondyloarthritis, who participated in the long-term (until year 10) extension o...

Long‑Term Certolizumab Pegol Treatment of Axial Spondyloarthritis Is Associated with Rapid and Sustained Reduction of Active Inflammation and Minimal Structural Changes in the Spine: 4‑Year MRI Res...
Xenofon Baraliakos, Sebastian Kruse, Simone Auteri et. al.

Nov 11th, 2019 - Background/Purpose: Inflammation of the spine is believed to trigger a repair mechanism that results in syndesmophyte formation in axial spondyloarthritis (axSpA) patients (pts).1 Bone marrow fatty lesions (FLs) and axial skeleton erosions, visible on MRI T1 sequences, are post‑inflammatory changes that contribute significantly to models predicting new bone formation.2 It has previously been as...

Long-Term Effectiveness and Safety of Infliximab and Golimumab in Ankylosing Spondylitis Patients from a Prospective Observational Registry
Proton Rahman, Derek Haaland, Dalton Sholter et. al.

Nov 11th, 2019 - Background/Purpose: Long-term registries are essential to evaluate new therapies in a patient population that differs from clinical trial and usually varies over time.  The purpose was to describe the profile of ankylosing spondylitis (AS) patients treated with infliximab (IFX) or golimumab (GLM) treatment in Canadian routine care along with its long-term effectiveness and safety. Methods: 810 ...

Golimumab as First, Second or at Least Third Biologic Agent in Patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) or Ankylosing Spondylitis (AS) – Post Hoc Analysis of a Non-Interve...
Klaus Krüger, Gerd Burmester, Siegfried Wassenberg et. al.

Nov 11th, 2019 - Background/Purpose: The aim of this post hoc analysis is to assess effectiveness of GLM used as first, second, or at least third biologic agent in RA, PsA and AS in a real-life setting. Methods: Post hoc analysis of the non-interventional, GO-NICE study with RA, PsA and AS patients starting GLM 50mg SC in a real practice setting in Germany, details were shown earlier (1,2). Endpoint measures DA...

Golimumab Improves Work Productivity and Activity and Quality of Life in Patients with Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA): Final Results from a Non...
Klaus Krüger, Sven Remstedt, Astrid Thiele 3 and Ines Klaudius et. al.

Nov 11th, 2019 - Background/Purpose: Golimumab (GLM) has shown its efficacy and tolerability in various randomized clinical trials. Systemic data for GLM regarding health-economic parameters in daily clinical practice are essential not only for pharmaceutical companies but also for cost-benefit analyses in Germany. This prospective NIS was designed to evaluate the impact of GLM therapy on work productivity and ...

Golimumab Persistence in Biologic Naive and Non-Naive Patients with Axial Spondyloarthritis: Results of the GO PRACTICE Study
René-Marc Flipo, Florence Tubach, Jean Ouaniche et. al.

Nov 11th, 2019 - Background/Purpose: The pivotal GO AFTER study [1] and the ongoing observational GO BEYOND study investigate GLM efficacy in rheumatoid arthritis (RA) patients who previously received biologics. However, clinical studies of GLM in axial spondyloarthritis (axSpA) are lacking. Using data from the GO PRACTICE study, we examined GLM persistence in patients with axSpA. The primary objective of the s...

Infliximab Serum Trough Levels Predict Non-clinical Response in Patients with Axial Spondyloarthritis
Chamaida Plasencia, Ana Martínez-Feito, Borja Hernández-Breijo et. al.

Nov 11th, 2019 - Background/Purpose: Infliximab (Ifx) has proven to be efficacious for improving symptoms in patients with axial SpA(axSpA).  Several factors may influence the pharmacokinetic-pharmacodynamic of Ifx and its relation with clinical response such as: disease activity, anti-drug antibodies and the use of concomitant conventional synthetic DMARDs. The prediction of early response through Ifx concentr...

Clinically Relevant Deficits in Performance Tests in Patients with Axial Spondyloarthritis(axSpA) – Collecting Questionnaires Is Insufficient
Uta Kiltz, Eerik Ahomaa, Björn Bühring et. al.

Nov 11th, 2019 - Background/Purpose: Physical function in axial spondyloarthritis (axSpA) usually assessed by the BASFI questionnaire is an established core domain of that disease. There is evidence that self- reported physical function is not equivalent with the actual performance of patients. Physical performance can be assessed as a single task such as grip strength or single stance, or as a generic compound...

Certolizumab Pegol-Treated Patients with Non-Radiographic Axial Spondyloarthritis Demonstrate Improvements in Sleep Quality and Other Patient Reported Outcomes
Lianne Gensler, Jonathan Kay, Walter P. Maksymowych et. al.

Nov 11th, 2019 - Background/Purpose: Pain, fatigue, morning stiffness and impaired sleep are some of the main symptoms contributing to reduced quality of life (QoL) in patients (pts) with non-radiographic axial spondyloarthritis (nr-axSpA).1 Additionally, pts who are poor sleepers have been shown to have higher disease activity, fatigue scores and nocturnal back pain.2 Certolizumab pegol (CZP) treatment has dem...

Cytokine Dependence of Enthesis-resident Lymphocytes in Murine Spondyloarthritis
Mederbek Matmusaev, Emma Haley, Imtiyaz Hossain 1 and Joerg Ermann et. al.

Nov 11th, 2019 - Background/Purpose: Enthesis-resident CD4-CD8- double-negative (DN) T cells have been implicated in the pathogenesis of spondyloarthritis. Overexpression of IL-23 in adult mice activates these cells to produce IL-17A and other pathogenic cytokines leading to spondyloarthritis-like disease. Many innate lymphocytes require IL-1 for IL-23-induced production of IL-17A in vitro. We therefore investi...

Cancer Risk in Patients with Ankylosing Spondylitis: A Nationwide Population-based Dynamic Cohort Study from Korea
Eunyoung Lee, Kyung-Do Han, Yeong-Wook Song 3 and Eun Young Lee et. al.

Nov 11th, 2019 - Background/Purpose: The aim of this study is to determine the risk of overall malignancy and site-specific cancer in ankylosing spondylitis (AS) patients compared with patients without AS in Korea. Methods: The study utilized the National Health Information Database managed by National Health Insurance Service in Korea. The data from national health screening programs, data related to medical c...

Certolizumab Pegol Improves Work and Household Productivity and Social Participation over 1 Year of Treatment in Patients with Non-Radiographic Axial Spondyloarthritis
Atul Deodhar, Lianne Gensler, Jonathan Kay et. al.

Nov 11th, 2019 - Background/Purpose: Patients (pts) with non-radiographic axial spondyloarthritis (nr-axSpA) report substantial impairment of productivity and daily activities due to the burden of their disease, similar to pts with ankylosing spondylitis.1,2 Certolizumab pegol (CZP) treatment has been shown to significantly improve work and household productivity and social participation compared to placebo (PB...

Characteristics of Patients with Seropositive or Seronegative Rheumatoid Arthritis, Psoriatic Arthritis, or Axial Spondyloarthritis: Data from the US-Based Corrona Rheumatoid Arthritis and Psoriati...
Alexis Ogdie, Mei Liu, Sabrina Rebello et. al.

Nov 11th, 2019 - Background/Purpose: Rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) share many clinical features but are differentiated by key clinical and molecular characteristics. Patients with RA are often seropositive (S+) for rheumatoid factor (RF) or anti-cyclic citrullinated peptide (CCP) antibodies, whereas those with PsA or axSpA are usually seronegative (S−)...

Clinical Manifestations and Management of US Patients with SAPHO (Synovitis, Acne, Pustulosis, Hyperostosis, Osteitis) Syndrome, a Retrospective Study
Delamo Bekele, Paras Karmacharya, Kerry Wright 2 and Clement Michet et. al.

Nov 11th, 2019 - Background/Purpose: The SAPHO syndrome is a rare inflammatory disorder of bones, joints and skin first coined by Chamot in 1987 characterized by synovitis, acne, pustulosis, hyperostosis and osteitis1. No validated diagnostic criteria exist; diagnostic delay is not uncommon and observational data from the Western Hemisphere is sparse Methods: Adult patients with a diagnosis of SAPHO seen betwee...

Does Retention and Remission Rates to 2nd and 3rd TNF Inhibitors in Patients with Axial Spondyloarthritis Depend on the Reason from Withdrawal to the Previous Treatment? – Real World Data from 12 E...
Lykke Midtbøll Ørnbjerg, Cecilie Heegaard Brahe, Anne Gitte Loft et. al.

Nov 11th, 2019 - Background/Purpose: Tumour necrosis factor inhibitors (TNFi) are efficacious in patients with axial spondyloarthritis (axSpA), but still some patients switch to a different TNFi because of adverse effects (AE) or lack of effect (LOE). The EuroSpA Collaboration has previously demonstrated a 1-year retention rate of 79% and 6 months LUNDEX adjusted BASDAI< 4 of 59%1 in patients initiating the fir...

Drug Survival and Safety of Biosimilar CT-P13 versus Reference Infliximab in Patients with Ankylosing Spondylitis: Data from the Korean College of Rheumatology Biologics Registry
Hyoun-Ah Kim, Eunyoung Lee, Sun Kyung Lee et. al.

Nov 11th, 2019 - Background/Purpose: CT-P13 is the first biosimilar of the reference infliximab (IFX) prescribed for rheumatoid arthritis, ankylosing spondylitis (AS), Crohn’s disease, ulcerative colitis, psoriasis, and psoriatic arthritis. There are few studies showing long-term, real-world data of its drug survival or safety. To evaluate drug retention, efficacy and safety of CT-P13 versus IFX in patients wit...

Development and Validation of a Preliminary MRI Sacroiliac Joint Composite Structural Damage Score in a 5-year Longitudinal Study of Patients with Axial Spondyloarthritis
Marie Wetterslev, Mikkel Østergaard, Inge Juul Sørensen et. al.

Nov 11th, 2019 - Background/Purpose: In patients with axial spondyloarthritis (axSpA), MRI reliably detects structural lesions in the sacroiliac joints (SIJs). The SPARCC Sacroiliac joint (SIJ) Structural Score (SSS)(1) is a reliable and validated method to assess the individual structural lesions of the SIJs, i.e. fat lesion, erosion, backfill (fat metaplasia in an erosion cavity) and ankylosis. Several MRI st...

Drug Survival of Secukinumab for Axial Spondyloarthritis in a Real-World Setting Possible Response Factors
Carolina Merino Argumanez, Valentina Emperiale, María Martín et. al.

Nov 11th, 2019 - Background/Purpose: Secukinumab is a newly introduced biologic therapy against IL-17 which has been proved effective in patients with ankylosing spondylitis (AS)  in clinical trials and it has been added to the most recent national and international treatment guidelines. However, real-world data of its use is still scarce. This study aims to analyze drug survival of secukinumab for axial spondy...

Development of Smart-phone Spondyloarthritis Management System and Real-world Study of Chinese Patients with Ankylosing Spondylitis
Xiaojian Ji, Jian Zhu, Jianglin Zhang 2 and Feng Huang et. al.

Nov 11th, 2019 - Background/Purpose: We developed a multipurpose digital platform, Smart-phone SpondyloArthritis Management System (SpAMS), based on two of the most important objectives: 1) for patients: to activate patient engagement and provide education about disease self-management and 2) for clinicians and researchers: to provide a new source of real-world data for the scientific community by collecting qu...

The Deubiquitinase TRABID Is a Potential Therapeutic Target in Spondyloarthritis
Daniele Mauro, Federica Macaluso, Alessandra Nerviani et. al.

Nov 11th, 2019 - Background/Purpose: Interleukin 12 (IL-12) and 23 (IL-23) may play a pivotal role in the pathogenesis of inflammatory diseases, including Spondyloarthritis (SpA). In mice, the deubiquitinase Trabid, encoded by Zranb1, participates to the epigenetic regulation of IL-12 and IL-23 genes via the stabilization of the histone demethylase JMJD2D. TRABID also regulates the methyltransferase EZH2, invol...

To Evaluate Spine Ankylosis, Vertebral Fractures and Bone Fragility on a Single Imaging Exam in Patients with Ankylosing Spondylitis: Myth or Reality?
caroline Morizot, Marine Fauny, Edem Allado et. al.

Nov 11th, 2019 - Background/Purpose: Spine ankylosis is a risk factor of osteoporosis and mortality in ankylosing spondylitis (AS). Recently, thoracic-abdomino-pelvic CT (TAP-CT) has demonstrated its ability to screen bone fragility through the scanographic bone attenuation coefficient of the first lumbar vertebra (SBAC-L1). CT-scans is a remarkable imaging technic to assess structural spine ankylosis and verte...

Real Life 12 Year Retention Rate of Subcutaneous Anti-TNF in Spondyloarthritis. Results from a Multicenter Cohort of 1170 Patients
Guy Baudens, Pascal Coquerelle, Marie-Helene Guyot et. al.

Nov 11th, 2019 - Background/Purpose: Drug survival is used as a tool for treatment effectiveness and safety especially in real-world data. The objective of the study was to evaluate long term survival of subcutaneous TNF inhibitors (TNFi)  in spondyloarthritis (SA) patients and to compared drug survival between the different lines. Methods: Multicentric, retrospective, longitudinal and observational study inclu...

Ixekizumab Is Effective in the Treatment of Radiographic Axial Spondyloarthritis Regardless of the Level of C-Reactive Protein or Magnetic Resonance Imaging Scores
Walter P. Maksymowych, Gaia Gallo, Rebecca Bolce et. al.

Nov 11th, 2019 - Background/Purpose: IL-17 plays an important role in the pathogenesis of radiographic axial spondyloarthritis (r-axSpA). Elevated CRP levels in serum predict response to TNF inhibitors (TNFi).1-4 The role of baseline spine MRI as a predictor of response has not been investigated for IL-17 inhibitors. This study evaluates response rates at week (wk) 16 with ixekizumab (IXE), an IL-17A antagonist...

Inflammatory Bowel Disease and Anterior Uveitis in Patients Treated with Ixekizumab for Radiographic Axial Spondyloarthritis: Results from Two Phase 3 Studies Through 52 Weeks
Sergio Schwartzman, Atul Deodhar, Andris Kronbergs et. al.

Nov 11th, 2019 - Background/Purpose: Radiographic axial spondyloarthritis (r-axSpA) is a chronic inflammatory disease involving the axial skeleton; inflammatory bowel disease (IBD) and acute anterior uveitis (AAU) are common extra-articular manifestations. IBD has been reported in 3–10% of ankylosing spondylitis (AS) patients (pts).1 Exposure-adjusted incidence rates (EAIRs) of IBD in AS pts treated with TNF in...

Impact of Age and Disease Duration on the Response to IL-17A Inhibitor (Secukinumab) Treatment in Ankylosing Spondylitis: Pooled Results from the Phase 3 MEASURE Studies
Atul Deodhar, Philip Mease, Paula Machado et. al.

Nov 11th, 2019 - Background/Purpose: Ankylosing spondylitis (AS), a chronic inflammatory disease involving the sacroiliac joints and spine, is associated with pain, stiffness, disability, and reduced quality of life.1,2 Therefore, prompt diagnosis and treatment of patients (pts) is critical. In this post hoc analysis, we assessed the impact of age and disease duration (DD; defined as time since diagnosis) on re...

Infections in Patients with Active Radiographic Axial Spondyloarthritis Treated with Ixekizumab in 2 Phase 3 Clinical Trials
Marina Magrey, Victoria Navarro-Compán, Sandra Garces et. al.

Nov 11th, 2019 - Background/Purpose: Ixekizumab (IXE) is a high-affinity monoclonal antibody that selectively targets IL-17A. IL-17 inhibitors have shown efficacy for radiographic axial spondyloarthritis (r-axSpA), with IXE currently under study. As biologics may be associated with increased infections, we report on infections in patients with active r-axSpA treated with IXE. Methods: Eligible patients met ASAS...

IL-17A Induces Distinct Functional Differences Between Two Novel Mesenchymal Stem Cell Populations Identified at the Human Enthesis
Tobias Russell, Abdulla Watad, Charlie Bridgewood et. al.

Nov 11th, 2019 - Background/Purpose: Ankylosing spondylitis (AS) is associated with entheseal inflammation and new bone formation. Resident populations of lymphocytes have been identified at the enthesis that on stimulation with IL-23 produce pro-inflammatory cytokines including IL-17A and IL-22 (1) which drive inflammation and may also influence osteogenesis. Surprisingly, enthesis resident mesenchymal stem ce...

Real World Effectiveness of Secukinumab in Patients with Ankylosing Spondylitis: Findings from a Recent Cross Sectional Survey of Rheumatologists and Patients in Europe
Uta Kiltz, Elizabeth Holdsworth, Haijun Tian et. al.

Nov 11th, 2019 - Background/Purpose: Ankylosing spondylitis (AS) can lead to reduced physical functioning and quality of life.  Secukinumab has demonstrated clinical benefits in AS patients in clinical trials1-2.  The purpose of this study was to assess effectiveness of secukinumab in AS in a real-world setting. Methods: This was a cross-sectional survey of rheumatologists and patients in France, Germany, Italy...

Real-Life Golimumab Persistence in Patients with Chronic Inflammatory Rheumatic Disease: Results of the GO PRACTICE Study
René-Marc Flipo, Florence Tubach, Jean Ouaniche et. al.

Nov 11th, 2019 - Background/Purpose: The GO PRACTICE study was initiated following a demand by the French Health Authorities for long-term data on the real-life use of golimumab (GLM) in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) or axial spondyloarthritis (axSpA). The primary objective was to assess the persistence of GLM over 2 years after initiation. Secondary objectives included eval...

Erosions Are the Most Often Reported Structural Lesion on MRI of the Sacroiliac Joints in axSpA Patients with IBP
Manouk de Hooge, Ann-Sophie De Craemer, Thomas Renson et. al.

Nov 11th, 2019 - Background/Purpose: HLA-B27 and sacroiliitis on MRI form the basis of the Assessment of SpondyloArthritis international Society (ASAS) axial spondyloarthritis (axSpA) classification criteria. In addition, while not an entry criterion of the classification criteria, inflammatory back pain (IBP) is fundamental in the axSpA diagnostic process and it is endorsed as referral parameter in primary car...

Effect of Long-Term Treatment with Secukinumab on Cardio-Metabolic Profile in Patients with Active Ankylosing Spondylitis and Psoriatic Arthritis: Pooled 3 Year Analysis
Iain McInnes, Dafna Gladman, Atul Deodhar et. al.

Nov 11th, 2019 - Background/Purpose: Systemic inflammation may influence cardio-metabolic profiles and increases the risk of CV disorders in ankylosing spondylitis (AS) and psoriatic arthritis (PsA) patients (pts)1. Treatment with tumor necrosis factor (TNF) and Janus Kinase inhibitors have reported increased total cholesterol (TC) and triglycerides (TG) despite reduction in inflammation2,3. Here, we present th...

Effects of Intravenous Golimumab, an Anti-TNFα Monoclonal Antibody, on Health-Related Quality of Life in Patients with Ankylosing Spondylitis: 1-Year Results of a Phase III Trial
John Reveille, Atul Deodhar, Diane Harrison et. al.

Nov 11th, 2019 - Background/Purpose: In patients with ankylosing spondylitis (AS), IV administration of the anti-TNFa antibody golimumab (GLM-IV) resulted in improvements in composite measures of various aspects of the disease (eg, ASAS percent response, BASDAI, and BASFI) that were greater than placebo (PBO) at week 16 or earlier in the GO-ALIVE study.1 The improvements were maintained for up to 1 year of trea...

Effectiveness of Switching Between TNF Inhibitors in Patients with Axial Spondyloarthritis: Is the Reason to Switch Relevant?
Santiago Rodrigues-Manica, Alexandre Sepriano, Fernando Pimentel-Santos et. al.

Nov 11th, 2019 - Background/Purpose: Over the last years, and mostly due to lack of alternatives, it has been common practice to start a second TNF inhibitor (TNFi) in patients with axial spondyloarthritis (axSpA) who discontinue their first TNFi. Evidence informing on the effectiveness of this strategy in clinical practice is limited. Importantly it remains unclear whether the reason for discontinuation of the...

Impact of TNF-α Inhibitor on Lipid Profile and Atherogenic Index of Plasma in Axial Spondyloarthritis: Two-year Follow-up Data from the Catholic Axial Spondyloarthritis COhort (CASCO)
Hong Ki Min, Seung-Ki Kwok 2 and Sang-Heon Lee, Konkuk university medical center et. al.

Nov 11th, 2019 - Background/Purpose: To evaluate the influence of TNF-α inhibitor on lipid profile and atherogenic index of plasma (AIP) in axial spondyloarthritis (axSpA) patients with long term use of stable dose TNF-α inhibitor. Methods: axSpA patients were enrolled in the Catholic Axial Spondyloarthritis COhort (CASCO). We collected their data annually and analyzed their lipid profile and AIP [logarithm of ...

Ixekizumab Improves Self-reported Overall Functioning and Health as Measured by the Assessment of SpondyloArthritis International Society Health Index in Patients with Active Radiographic Axial Spo...
Uta Kiltz, Désirée van der Heijde, Annelies Boonen et. al.

Nov 11th, 2019 - Background/Purpose: The Assessment of SpondyloArthritis international Society Health Index (ASAS HI) measures health, disability, and functioning in patients (pts) with spondyloarthritis (SpA)[1,2]. The purpose of this study was to assess the impact of 52 weeks of ixekizumab (IXE) treatment on overall functioning and health in 2 phase 3 trials of pts with ankylosing spondylitis (AS)/radiographi...

Inflammatory Processes in Experimental Spondyloarthritis Are Accompanied by Formation of Ectopic Lymphoid Structures and B Cell Lineage Alterations in the Bone Marrow
Merlijn Kaaij, Jan Piet van Hamburg, Jasper Rip et. al.

Nov 11th, 2019 - Background/Purpose: Tumour necrosis factor a (TNF) is important in immune-mediated inflammatory diseases such as spondyloarthritis (SpA). Transmembrane ™TNF-transgenic (tg) mice that overexpress tmTNF develop typical SpA symptoms, including inflammation, bone destruction and bone formation. Interestingly, these mice also develop lymphoid aggregates in the bone marrow (BM) of the axial and perip...

Ixekizumab Improves Fatigue, Pain, and Sleep up to 52 Weeks in Patients with Radiographic Axial Spondyloarthritis
Atul Deodhar, Philip Mease, Proton Rahman et. al.

Nov 11th, 2019 - Background/Purpose: Axial spondyloarthritis (axSpA) is an inflammatory condition affecting sacroiliac joints and axial skeleton, characterized by fatigue, spinal pain, and sleep disturbances that negatively affect patient health-related quality of life.1 Ixekizumab (IXE) has demonstrated efficacy in treatment of radiographic axial spondyloarthritis (r-axSpA) in both biologic disease-modifying a...

6 and 12-month Drug Retention Rates and Treatment Outcomes in 941 Patients with Axial Spondyloarthritis Treated with Secukinumab in Routine Clinical Practice in 12 European Countries in the EuroSpA...
Brigitte Michelsen, Johan Askling, Catalin Codreanu et. al.

Nov 11th, 2019 - Background/Purpose: Secukinumab is a fully human IgG1 monoclonal antibody targeting interleukin-17A. There is a lack of real-life evidence on secukinumab retention rates and treatment outcomes in axial spondyloarthritis (axSpA) patients. Hence, the aim of this study was to determine the 6- and 12-month secukinumab retention rates as well as the crude and LUNDEX corrected proportions of patients...

Associations of HLA-B Alleles, Enthesitis and Peripheral Arthritis in Ankylosing Spondylitis
Benjamin Naovarat, Michael Weisman, Lianne Gensler et. al.

Nov 11th, 2019 - Background/Purpose: Recent studies have suggested that peripheral arthritis in patients with spondyloarthritis is associated with HLA-B*15. Studies of white patients with psoriatic arthritis (PsA) have demonstrated associations with HLA-B*27, B*38, B*08 and B*37, whereas B*44 was associated with presence of milder disease. The purpose of this study was to examine HLA-B allele associations with ...

Tendon T-cell Interactions as Drivers of Chronicity in Spondyloarthritis
Emma Garcia-Melchor, Giacomo Cafaro, Hanna Johnsson et. al.

Nov 11th, 2019 - Background/Purpose: Emerging evidence supports the concept that stromal cell functions extend beyond maintenance of tissue architecture, exerting a key role in choreographing immune responses and thereby defining disease persistence. Accordingly, as enthesitis is a hallmark of spondyloarthropaties (SpA), we propose an interplay between tendon stromal cells (tenocytes) and the adaptive immune sy...

The Utility of Fat Lesions in Close Relation to Other Structural MRI Lesions in the Sacroiliac Joints for Diagnosing Patients with Axial Spondyloarthritis
Sengül Seven, Mikkel Østergaard, Lone Morsel-Carlsen et. al.

Nov 11th, 2019 - Background/Purpose: Bone marrow edema on MRI of the sacroiliac joints (SIJ) plays an important role in the ASAS (Assessment of Spondyloarthritis International Society) classification criteria for axial spondyloarthritis (axSpA). However, these lesions can also be seen in other conditions1 2. Structural SIJ MRI lesion characteristics may be of importance for differentiating patients with axSpA f...

The Ankylosing Spondylitis Disease Activity Score Reflects and Predicts Response to Biologic Treatment in Axial Spondyloarthritis Patients with Coexistent Fibromyalgia Compared to the Bath Ankylosi...
Sarah Sacks, Kathryn Rigler 2 and Antoni Chan, Royal Berkshire Hospital et. al.

Nov 11th, 2019 - Background/Purpose: Currently the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Spinal pain are used to assess whether a patient with Axial Spondyloarthritis (AxSpA) requires biologic therapy and their response to biologic therapy.  However, the BASDAI does not just reflect inflammatory disease activity as it includes questions relating to fatigue (question 1) and musculoskele...

Targeting the Oxidative Stress Pathway in Experimental Spondyloarthritis Reduces Pro-inflammatory Response in Rat Macrophages and Modulates Their Metabolic Requirements
Fatemeh Navid, Francesca LiCausi, Breanna Nguyen et. al.

Nov 11th, 2019 - Background/Purpose: HLA-B27 is associated with the development of spondyloarthritis (SpA) and has a tendency to generate ER stress due to misfolding which can activate the unfolded protein response (UPR). UPR may contribute to SpA pathogenesis by promoting the production of pro-inflammatory cytokines like IL-23 and TNF. Under ER stress cells produce more reactive oxygen species (ROS), which fur...

Epidemology, Clinical Features and Relationship to Biological Therapy of Uveitis in Axial Spondyloarthritis: Single Center University Study
Iñigo Gonzalez-Mazon, Lara Sanchez-Bilbao, Javier Rueda-Gotor et. al.

Nov 11th, 2019 - Background/Purpose: Uveitis is one of the most frequent extra articular manifestation of spondyloarthritis (SpA). Biological therapy, especially monoclonal TNF inhibitors, are useful to prevent and to treat refractory non-infectious uveitis. However, other biologics had been related to paradoxical uveitis. Our aim was to assess a) the epidemiological and clinical features of uveitis associated ...

Effects of Anti-TNF on MiR Expression in Monocytes and CD4+ T-Lymphocytes in Spondyloarthritis
Olivier Fogel, Maud Fagny, Elodie Roche et. al.

Nov 11th, 2019 - Background/Purpose: TNFα inhibitors are an effective treatment for many inflammatory diseases. However, their mechanism of action is more complicated than just blocking the targeted cytokine. MicroRNAs are important post-translational regulators of gene expression and their expression has been found deregulated in rheumatic diseases such as rheumatoid arthritis or spondyloarthritis. The general...

Entheseal CD90+ SOX9+ Cartilage-like Cells Initiate Spinal Ankylosis in Ankylosing Spondylitis
Sungsin Jo, Young Lim Lee, Tae-Han Lee et. al.

Nov 11th, 2019 - Background/Purpose: Enthesitis is characterized by inflammation at the interface where tendon or ligament attaches to the bone and is a representative symptom of ankylosing spondylitis(AS). The enthesitis is primarily responsible for the initiation and progression of AS. However, it is not known which cellular and molecular characterizations of enthesitis contribute to cartilage fusion and ench...

Exposure-Response Analyses for Upadacitinib Efficacy and Safety in Ankylosing Spondylitis – Analyses of the SELECT-AXIS I Study
Mohamed Ismail, Ahmed Nader, Insa Winzenborg et. al.

Nov 11th, 2019 - Background/Purpose: Upadacitinib, a selective inhibitor of Janus kinase 1 (JAK1), is currently being evaluated for the treatment of several autoimmune disorders, including axial spondyloarthritis (axial SpA).  In the SELECT-AXIS I study (NCT03178487), upadacitinib 15 mg once-daily (QD) demonstrated favorable efficacy in ankylosing spondylitis (AS) patients who had an inadequate response to non-...

Effectiveness and Retention Rate of Secukinumab for Psoriatic Arthritis and Axial Spondyloarthritis: Real-life Data from the Italian LORHEN Registry
Ennio Giulio Favalli, Antonio Marchesoni, Silvia Balduzzi et. al.

Nov 11th, 2019 - Background/Purpose: Observational data on the use of secukinumab for the treatment of spondyloarthritides are still lacking. The aim of this study is to evaluate the effectiveness and the 3-year retention rate of secukinumab in psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) patients in a real-life setting.  Methods: Data of all PsA and axSpA patients (diagnosed according to CASPA...

Secukinumab Provides Sustained Improvement of Enthesitis in Ankylosing Spondylitis Patients: A Pooled Analysis of Four Pivotal Phase 3 Trials
Georg Schett, Xenofon Baraliakos, Filip Van den Bosch et. al.

Nov 11th, 2019 - Background/Purpose: Enthesitis can be a debilitating spondyloarthritis (SpA) manifestation and the cause of pain, reduced quality of life and impaired physical function.1,2 Herein, we evaluated the effect of secukinumab on axial and peripheral enthesitis in ankylosing spondylitis (AS) patients with baseline enthesitis (BLE) across all Maastricht AS EnthesiS (MASES) sites (N=13), axial sites [N=...

Vaspin rs35262691 Is Associated with Atherosclerotic Disease in Axial Spondyloarthritis Patients
Fernanda Genre, Javier Rueda-Gotor, Sara Remuzgo-Martinez et. al.

Nov 11th, 2019 - Background/Purpose: Vaspin is a novel adipokine with insulin-sensitizing functions that exerts anti-inflammatory actions1,2. It has been associated with cardiovascular (CV) disease, CV risk factors and inflammation in the general population and in chronic inflammatory conditions different from axial SpA (axSpA)2-4. In particular, it has been suggested that vaspin may act as a compensatory mecha...

The Efficacy and Safety of Anti-TNFα Treatment in Ankylosing Spondylitis Patients with Late Onset Compared to Those with Adult Onset; The Data from TURKBIO Registry
Sadettin Uslu, Gercek Can, Ayşe Cefle et. al.

Nov 11th, 2019 - Background/Purpose: The first symptoms of ankylosing spondylitis (AS) patients usually begin prior to 45 years, but can occur later in life. The purpose of this study is to evaluate the efficacy and safety of anti-TNFα treatment in late-onset AS (LoAS) patients in comparison to those with adult onset AS (AoAS). Methods: We studied AS patients in TURKBIO registry between the dates of January 201...

Persistence with Etanercept in Patients with Ankylosing Spondylitis or Psoriatic Arthritis in Germany: A Real-World Analysis
Xenofon Baraliakos, Denis Poddubnyy, Frank Behrens et. al.

Nov 11th, 2019 - Background/Purpose: Ankylosing spondylitis (AS) and psoriatic arthritis (PsA) treatment includes biologics, prescribed on a long-term basis. As persistence data from real-world practice are limited, the current study analyzes persistence with etanercept treatment for up to 5 years in AS or PsA patients in Germany. Methods: Patients diagnosed with AS or PsA with a first etanercept bio-original (...

Preliminary Identification of Arthritis-Associated Microbiota in Experimental Spondyloarthritis
Tejpal Gill, Tri Tran, Stephen Brooks 3 and Robert Colbert et. al.

Nov 11th, 2019 - Background/Purpose: Gut microbiota are strongly implicated in the pathogenesis of spondyloarthritis (SpA). Previous studies from our lab have documented extensive gut microbial dysbiosis in rats expressing HLA-B27 and human b2-microglobulin (HLA-B27 TG). The relative abundance of individual microbes is highly dependent on host genetic and environmental differences despite common immune dysregul...

Patient Reported Outcomes over Time in 25,988 Axial Spondyloarthritis Patients Initiating Treatment with 1st, 2nd or 3rd TNF Inhibitor in Clinical Practice – Is PRO Remission Achieved? Results from...
Lykke Midtbøll Ørnbjerg, Johan Askling, Anne Gitte Loft et. al.

Nov 11th, 2019 - Background/Purpose: Treatment effectiveness in patients with axial spondylarthritis (axSpA) is evaluated by a combination of objective markers of disease activity and patient reported outcomes (PROs), e.g. pain, physical function, fatigue and global scores. Development in PROs over time in patients, who initiate treatment with their 1st, 2nd or 3rd Tumour Necrosis Factor inhibitor (TNFi) in rou...

Predictors of Response, Adverse Events and Treatment Retention in Ankylosing Spondylitis Patients Treated with Golimumab in a Prospective, Observational Registry
Proton Rahman, Ariel Masetto, Michelle Teo et. al.

Nov 11th, 2019 - Background/Purpose: The Biologic Treatment Registry Across Canada (BioTRAC) was a prospective, observational registry that enrolled ankylosing spondylitis (AS) (radiographic axial SpA) patients treated with subcutaneous golimumab (GLM) between 2010 and 2017. The registry was closed in June 2018. Methods: Patient visits occurred at baseline and every 6 months thereafter. Multivariate logistic re...

Predicting Response to Biologic Therapy in Patients with Axial Spondyloarthritis (axSpA)
Gareth Jones, Linda Dean, Ejaz Pathan 2 and Gary Macfarlane et. al.

Nov 11th, 2019 - Background/Purpose: In axial spondyloarthritis (axSpA), the clinical benefits of TNF inhibition (TNFi) are well documented although, by design, most studies report average benefits in groups of patients.  Inevitably, a subset of patients will not respond to therapy.  Identifying characteristics of these patients is important as it may inform the use of TNFi in clinical practice.  The aim of the...

Ixekizumab: 52-Week Efficacy and Safety in Radiographic Axial Spondyloarthritis Patients with Prior Inadequate Response/Intolerance to Tumor Necrosis Factor Inhibitors
Maxime Dougados, Joachim Sieper, Xenofon Baraliakos et. al.

Nov 11th, 2019 - Background/Purpose: Week 16 results from COAST-W (NCT02696798) showed that ixekizumab (IXE) was superior to placebo (PBO) in improving the signs and symptoms of active radiographic axial spondyloarthritis (r-axSpA) in patients with prior inadequate response (IR) or intolerance to tumor necrosis factor inhibitors (TNFi).1 Long-term efficacy and safety of IXE in this population have not been repo...

Baseline Characteristics and Natural History of Radiographic versus Non-radiographic Axial Spondyloarthritis: 5 Years Follow-up of the Desir Cohort
Clementina López-Medina, Anna Moltó, Pascal Claudepierre 3 and Maxime Dougados et. al.

Nov 10th, 2019 - Background/Purpose: There is still a debate concerning the concept of non-radiographic (nr-axSpA) axial Spondyloarthritis (e.g. to consider it as a distinct entity from r-axSpA (Ankylosing Spondylitis) or to consider it as the same disease with different phenotypical presentations). This study aims to compare clinical manifestations and burden of disease between r-axSpA and nr-axSpA over 5 year...

Prevalence of Radiographic Entheseal Lesions at the Hip and Pelvic Region in Patients with Ankylosing Spondylitis versus Controls
Freke Wink, Thomas Diemel, Suzanne Arends 2 and Anneke Spoorenberg et. al.

Nov 10th, 2019 - Background/Purpose: Enthesitis is one of the features of ankylosing spondylitis (AS). High prevalence of structural and inflammatory ultrasound lesions of peripheral entheses are found in AS patients. Furthermore, plain radiographs provide good imaging of peripheral enthesopathy at well-defined skeletal sites1. There are several entheseal sites at the pelvis and hip region, but little is known ...

MRI of the Sacroiliac Joints in Athletes: Do Semi-axial Slices Added to Standard Semi-coronal Scans Facilitate Recognition of Non-specific Bone Marrow Edema?
Ulrich Weber, Anne Grethe Jurik, Anna Zejden et. al.

Nov 10th, 2019 - Background/Purpose: Low grade bone marrow edema (BME) on magnetic resonance imaging (MRI) of the sacroiliac joints (SIJ) is challenging the discrimination between patients with early axial spondyloarthritis (SpA) and mechanical back pain. In our previous analysis, recreational and elite athletes had on average 3-4 SIJ quadrants with BME, and 30-41% met the Assessment of SpondyloArthritis intern...

Macrophage Migration Inhibitory Factor Is a Critical Regulator in a Mouse Model of Spondyloarthritis
Akihiro Nakamura, Fanxing Zeng, Sayaka Nakamura et. al.

Nov 10th, 2019 - Background/Purpose: Spondyloarthritis (SpA) is a chronic rheumatic disease characterized by severe inflammation in the spine, peripheral joints, intestine, skin and eyes. Although current treatment modalities including tumor-necrosis-factor (TNF) and interleukin (IL)-17 blockers could control inflammation, up to 40% of SpA patients don’t adequately response to any medications or lose their effi...

Metabolomics Screening in Axial Spondyloarthritis: Identifying Potential Biomarkers
Andrew Stahly, Emilie Regner, Adam Lefferts et. al.

Nov 10th, 2019 - Background/Purpose: Early intervention in axial spondyloarthritis (axSpA) may prevent pathogenic changes such as bone remodeling and spinal fusion. Unfortunately, early intervention is difficult, as there remains an average 5-10 year gap between onset of symptoms and diagnosis partly due to a lack of diagnostic biomarkers. Currently, diagnosis is based on a combination of clinical features, inf...

Muscle Physical Properties in Young Adult Axial Spondyloarthritis Patients, the MyoSpA Study
Fernando Pimentel-Santos, Agna Neto, Lúcia Domingues et. al.

Nov 10th, 2019 - Background/Purpose: An important mechanism regarding axial spondyloarthritis (axSpA) susceptibility and progression is the biomechanical concept, suspected from axial myofascial hypertonicity and stiffness in ankylosing spondylitis (AS). This pathway may promote local tissue microtrauma and contribute to immunological activation and subsequent bony fusion or ankylosis. The MyoSpA study tests th...